These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 10508712)

  • 1. Recombinant antibody constructs in cancer therapy.
    Hudson PJ
    Curr Opin Immunol; 1999 Oct; 11(5):548-57. PubMed ID: 10508712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant antibodies: a novel approach to cancer diagnosis and therapy.
    Hudson PJ
    Expert Opin Investig Drugs; 2000 Jun; 9(6):1231-42. PubMed ID: 11060739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant antibody fragments.
    Hudson PJ
    Curr Opin Biotechnol; 1998 Aug; 9(4):395-402. PubMed ID: 9720265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant antibodies for cancer diagnosis and therapy.
    Souriau C; Hudson PJ
    Expert Opin Biol Ther; 2003 Apr; 3(2):305-18. PubMed ID: 12662144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody engineering: facing new challenges in cancer therapy.
    Sanz L; Cuesta AM; Compte M; Alvarez-Vallina L
    Acta Pharmacol Sin; 2005 Jun; 26(6):641-8. PubMed ID: 15916728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant bispecific antibodies for cellular cancer immunotherapy.
    Müller D; Kontermann RE
    Curr Opin Mol Ther; 2007 Aug; 9(4):319-26. PubMed ID: 17694444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition.
    Croasdale R; Wartha K; Schanzer JM; Kuenkele KP; Ries C; Mayer K; Gassner C; Wagner M; Dimoudis N; Herter S; Jaeger C; Ferrara C; Hoffmann E; Kling L; Lau W; Staack RF; Heinrich J; Scheuer W; Stracke J; Gerdes C; Brinkmann U; Umana P; Klein C
    Arch Biochem Biophys; 2012 Oct; 526(2):206-18. PubMed ID: 22464987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Numerical selection of optimal tumor imaging agents with application to engineered antibodies.
    Williams LE; Wu AM; Yazaki PJ; Liu A; Raubitschek AA; Shively JE; Wong JY
    Cancer Biother Radiopharm; 2001 Feb; 16(1):25-35. PubMed ID: 11279795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant antibodies for cancer diagnosis and therapy.
    Hudson PJ; Souriau C
    Expert Opin Biol Ther; 2001 Sep; 1(5):845-55. PubMed ID: 11728219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineering therapeutic monoclonal antibodies.
    Liu XY; Pop LM; Vitetta ES
    Immunol Rev; 2008 Apr; 222():9-27. PubMed ID: 18363992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineering antibodies for imaging and therapy.
    Carter P; Merchant AM
    Curr Opin Biotechnol; 1997 Aug; 8(4):449-54. PubMed ID: 9265724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multivalency: the hallmark of antibodies used for optimization of tumor targeting by design.
    Deyev SM; Lebedenko EN
    Bioessays; 2008 Sep; 30(9):904-18. PubMed ID: 18693269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Applications for an engineered Protein-G variant with a pH controllable affinity to antibody fragments.
    Bailey LJ; Sheehy KM; Hoey RJ; Schaefer ZP; Ura M; Kossiakoff AA
    J Immunol Methods; 2014 Dec; 415():24-30. PubMed ID: 25450256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transient expression of human antibodies in mammalian cells.
    Vazquez-Lombardi R; Nevoltris D; Luthra A; Schofield P; Zimmermann C; Christ D
    Nat Protoc; 2018 Jan; 13(1):99-117. PubMed ID: 29240734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant antibodies as therapeutic agents: pathways for modeling new biodrugs.
    Aires da Silva F; Corte-Real S; Goncalves J
    BioDrugs; 2008; 22(5):301-14. PubMed ID: 18778112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineering mouse monoclonal antibodies for cancer immunotherapy.
    Orlandi R
    Year Immunol; 1993; 7():69-73. PubMed ID: 8372514
    [No Abstract]   [Full Text] [Related]  

  • 17. Bispecific antibodies for cancer therapy.
    Hollander N
    Immunotherapy; 2009 Mar; 1(2):211-22. PubMed ID: 20635943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibodies as carriers of toxins.
    Uhr JW; Fulton RJ; Till MA; May RD; Vitetta ES
    Prog Clin Biol Res; 1989; 288():403-12. PubMed ID: 2785694
    [No Abstract]   [Full Text] [Related]  

  • 19. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
    Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodies.
    Muda M; Gross AW; Dawson JP; He C; Kurosawa E; Schweickhardt R; Dugas M; Soloviev M; Bernhardt A; Fischer D; Wesolowski JS; Kelton C; Neuteboom B; Hock B
    Protein Eng Des Sel; 2011 May; 24(5):447-54. PubMed ID: 21498564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.